Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $80 | $250 | $41 | $37 |
| % Growth | -68% | 511.2% | 9.3% | – |
| Cost of Goods Sold | $0 | $92 | $56 | $74 |
| Gross Profit | $80 | $158 | -$15 | -$36 |
| % Margin | 100% | 63.1% | -36.3% | -97.2% |
| R&D Expenses | $127 | $92 | $61 | $74 |
| G&A Expenses | $36 | $36 | $31 | $37 |
| SG&A Expenses | $36 | $36 | $31 | $37 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$92 | -$56 | -$74 |
| Operating Expenses | $163 | $36 | $36 | $37 |
| Operating Income | -$83 | $122 | -$51 | -$74 |
| % Margin | -104.1% | 48.8% | -124.3% | -196.8% |
| Other Income/Exp. Net | $19 | $12 | $4 | $2 |
| Pre-Tax Income | -$64 | $134 | -$46 | -$71 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | -$65 | $132 | -$46 | -$71 |
| % Margin | -81.3% | 52.9% | -113.4% | -190.3% |
| EPS | -1.13 | 3.08 | -1.21 | -1.75 |
| % Growth | -136.7% | 354.5% | 30.9% | – |
| EPS Diluted | -1.13 | 2.97 | -1.21 | -1.75 |
| Weighted Avg Shares Out | 58 | 43 | 38 | 38 |
| Weighted Avg Shares Out Dil | 58 | 45 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $12 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $4 | $6 | $5 |
| EBITDA | -$79 | $126 | -$40 | -$68 |
| % Margin | -98.2% | 50.6% | -96.9% | -183% |